Cochrane Review Finds Medical Cannabis Fails to Meaningfully Improve Sleep in Adults With Insomnia

More Americans than ever are reaching for cannabis to get a better night's sleep. The evidence says they're probably not getting what they're paying for.

A Cochrane systematic review published in the Cochrane Database of Systematic Reviews concluded that medical cannabis has little to no clinically meaningful effect on sleep quality, total sleep time, or daytime functioning in adults diagnosed with insomnia. The review, led by researchers at the Cochrane Associate Centre at the Universidad Hospital Italiano de Buenos Aires and the University of Manitoba, pulled together data from nine randomized controlled trials covering 537 adults between the ages of 18 and 76.

Eight of those nine trials compared regulated medical cannabis products against a placebo. One compared cannabis against the antidepressant amitriptyline. Across the placebo comparisons, reviewers found no clear, clinically meaningful improvement in any of the three outcomes they set out to measure: how well people slept, how long they slept, and how they functioned the next day.

The numbers behind that finding are worth spelling out. According to a summary reviewed by Medscape, the mean difference in total sleep time between cannabis and placebo was just under eight minutes, with a confidence interval wide enough to include both a loss and a gain of roughly 23 minutes. That's not a treatment signal. That's noise.

The review also flagged a safety concern that tends to get lost in popular coverage of cannabis as a natural remedy. According to the European Medical Journal, medical cannabis may increase adverse events compared with placebo, with an odds ratio above 11. Participants reported more dry mouth and dizziness than those on placebo. That's a real tradeoff for a product that's being marketed, often implicitly, as gentler than a sleeping pill.

Quality of life did show a possible improvement in one part of the analysis, but the reviewers rated that evidence as very low certainty, meaning pooled results were compatible with anything from a slight worsening to a large benefit. That's not a finding you can act on clinically.

The review's authors were careful not to declare cannabis ineffective. As reported by Medical Xpress in coverage of the Cochrane findings, the central message is that the research isn't yet sufficient to reliably answer the question, not that the answer is definitely no. What it does establish is that interest in medical cannabis for sleep has well outpaced the evidence supporting it.

There are real gaps in what these trials can tell us. Most of the participants in the included studies were adults with insomnia as their primary complaint, so the findings may not transfer neatly to older patients, people whose sleep disruption comes from chronic pain or psychiatric conditions, or anyone who's been using cannabis for years rather than weeks. The trials were also short, which limits what anyone can say about sustained benefit or long-term risk.

For clinicians managing patients who are already self-medicating with cannabis for sleep, the review offers a useful frame: uncertainty is not permission. Patients deserve to know the evidence base for what they're taking is thin, and they deserve a conversation about what that means for their care plan.

Sleep medicine specialists and primary care physicians who counsel patients on insomnia have more options with clearer evidence behind them, including cognitive behavioral therapy for insomnia, which has the most robust trial data in the field, and certain short-term pharmacologic options. The Cochrane findings don't close the door on cannabis research. They do suggest the marketing has been running far ahead of the science.

Sources cited:
- Cochrane Database of Systematic Reviews (https://cochranelibrary.com/web/cochrane/content?contentLanguage=&doi=10.1002%2F14651858.CD016216.pub2&templateType=full&type=cdsr&urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD016216.pub2)
- Medscape (https://www.medscape.com/viewarticle/medical-cannabis-shows-little-benefit-insomnia-adults-2026a10012lb)
- Medical Xpress (https://medicalxpress.com/news/2026-10-insufficient-evidence-medical-cannabis-insomnia.html)
- European Medical Journal (EMJ) (https://www.emjreviews.com/innovations/news/medical-cannabis-for-insomnia-shows-limited-benefits/)